Multidose evaluation of 6,710 drug repurposing library identifies potent SARS-CoV-2 infection inhibitors In Vitro and In Vivo.
Patten, J.; Keiser, P. T.; Gysi, D. M.; Menichetti, G.; Mori, H.; Donahue, C. J.; Gan, X.; do Valle, I. F.; Geoghegan-Barek, K.; Anantpadma, M.; Berrigan, J. L.; Jalloh, S. C.; Ayazika, K. T.; Wagner, F.; Zitnik, M.; Ayehunie, S.; Anderson, D.; Loscalzo, J.; Gummuluru, S.; Namchuk, M. N.; Barabasi, A.-L.; Davey, R. A.
Show abstract
Identification of host factors contributing to replication of viruses and resulting disease progression remains a promising approach for development of new therapeutics. Here, we evaluated 6710 clinical and preclinical compounds targeting 2183 host proteins by immunocytofluorescence-based screening to identify SARS-CoV-2 infection inhibitors. Computationally integrating relationships between small molecule structure, dose-response antiviral activity, host target and cell interactome networking produced cellular networks important for infection. This analysis revealed 389 small molecules, >12 scaffold classes and 813 host targets with micromolar to low nanomolar activities. From these classes, representatives were extensively evaluated for mechanism of action in stable and primary human cell models, and additionally against Beta and Delta SARS-CoV-2 variants and MERS-CoV. One promising candidate, obatoclax, significantly reduced SARS-CoV-2 viral lung load in mice. Ultimately, this work establishes a rigorous approach for future pharmacological and computational identification of novel host factor dependencies and treatments for viral diseases.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 97%
- Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 96%
- Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture 95%
Similar papers in this journal
Similar papers in this journal
- Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 98%
- The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern 95%
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 95%
Similar papers in this journal
- A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells 96%
- Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection 96%
- 2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.